These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31092376)

  • 1. Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases.
    Ponce S; Bruna J; Juan O; López R; Navarro A; Ortega AL; Puente J; Verger E; Bartolomé A; Nadal E
    Crit Rev Oncol Hematol; 2019 Jun; 138():190-206. PubMed ID: 31092376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion.
    Hendriks LEL; Dooms C; Berghmans T; Novello S; Levy A; De Ruysscher D; Hasan B; Giaj Levra M; Giaj Levra N; Besse B; Vansteenkiste J; Dingemans AC;
    Eur J Cancer; 2019 Dec; 123():28-35. PubMed ID: 31655358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Far Posterior Approach for Rib Fracture Fixation: Surgical Technique and Tips.
    Manes TJ; DeGenova DT; Taylor BC; Patel JN
    JBJS Essent Surg Tech; 2024; 14(4):. PubMed ID: 39650795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation.
    Pang LL; Zhuang WT; Li JJ; Li B; Huang YH; Liao J; Li MD; Zhang L; Fang WF
    Neoplasia; 2024 Dec; 58():101073. PubMed ID: 39427513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
    Lu S; Ahn MJ; Reungwetwattana T; Özgüroğlu M; Kato T; Yang JC; Huang M; Fujiki F; Inoue T; Quang LV; Sriuranpong V; Vicente D; Fuentes C; Chaudhry AA; Poole L; Armenteros Monterroso E; Rukazenkov Y; van der Gronde T; Ramalingam SS
    Ann Oncol; 2024 Dec; 35(12):1116-1125. PubMed ID: 39289145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician preferences of biomarker testing strategies in newly diagnosed stage IV non-small cell lung cancer patients.
    Shah A; Apple J; Burgos G; Lankin J; Cohn J; Mulvihill E; Cambron-Mellott MJ
    Future Oncol; 2024 Dec; 20(39):3229-3243. PubMed ID: 39552591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in Māori and Pacifica in New Zealand.
    Aye PS; McKeage MJ; Tin Tin S; Khwaounjoo P; Elwood JM
    PLoS One; 2021; 16(5):e0251357. PubMed ID: 33961689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.
    Wang M; Fan Y; Sun M; Wang Y; Zhao Y; Jin B; Hu Y; Han Z; Song X; Liu A; Tang K; Ding C; Liang L; Wu L; Gao J; Wang J; Cheng Y; Zhou J; He Y; Dong X; Yao Y; Yu Y; Wang H; Sun S; Huang J; Fang J; Li W; Wang L; Ren X; Zhou C; Hu Y; Zhao D; Yang R; Xu F; Huang Y; Pan Y; Cui J; Xu Y; Yang Z; Shi Y
    Lancet Respir Med; 2024 Mar; 12(3):217-224. PubMed ID: 38101437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review.
    Nepote A; Poletto S; Bertaglia V; Carnio S; Piumatti C; Lanzetta C; Cantale O; Saba G; Bironzo P; Novello S; Tralongo AC
    Crit Rev Oncol Hematol; 2025 Jan; 205():104540. PubMed ID: 39486561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Review of Epidermal Growth Factor Receptor Mutation Abundance in Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
    Zeng L; Dai Y; Liu Y; Song B; Lin H; Xiao J
    Oncol Res Treat; 2024; 47(12):602-609. PubMed ID: 39353410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conservative, physical and surgical interventions for managing faecal incontinence and constipation in adults with central neurological diseases.
    Todd CL; Johnson EE; Stewart F; Wallace SA; Bryant A; Woodward S; Norton C
    Cochrane Database Syst Rev; 2024 Oct; 10(10):CD002115. PubMed ID: 39470206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
    Han JY; Ahn MJ; Lee KH; Lee YG; Kim DW; Min YJ; Kim SW; Cho EK; Kim JH; Lee GW; Lee SS; Lee NM; Jang HW; Han H; Park H; Lee J; Cho BC
    BMC Med; 2024 Oct; 22(1):428. PubMed ID: 39379931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
    Karayama M; Suda T; Yoh K; Usui K; Hosomi Y; Kishi K; Naka G; Watanabe K; Tamano S; Uemura K; Kunitoh H
    Lung Cancer; 2024 Dec; 198():108037. PubMed ID: 39602849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualitative evidence synthesis informing our understanding of people's perceptions and experiences of targeted digital communication.
    Ryan R; Hill S
    Cochrane Database Syst Rev; 2019 Oct; 10(10):ED000141. PubMed ID: 31643081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma-Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2024; 24(8):1-306. PubMed ID: 39698418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness of school-based family asthma educational programs on the quality of life and number of asthma exacerbations of children aged five to 18 years diagnosed with asthma: a systematic review protocol.
    Walter H; Sadeque-Iqbal F; Ulysse R; Castillo D; Fitzpatrick A; Singleton J
    JBI Database System Rev Implement Rep; 2015 Oct; 13(10):69-81. PubMed ID: 26571284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.